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Abstract
Sirtuin genes have been associated with aging and are known to affect multiple cellular
pathways. Sirtuin 2 was previously shown to modulate proteotoxicity associated with age-
associated neurodegenerative disorders such as Alzheimer and Parkinson disease (PD).
However, the precise molecular mechanisms involved remain unclear. Here, we provide
mechanistic insight into the interplay between sirtuin 2 and α-synuclein, the major compo-
nent of the pathognomonic protein inclusions in PD and other synucleinopathies. We found
that α-synuclein is acetylated on lysines 6 and 10 and that these residues are deacetylated
by sirtuin 2. Genetic manipulation of sirtuin 2 levels in vitro and in vivo modulates the levels
of α-synuclein acetylation, its aggregation, and autophagy. Strikingly, mutants blocking
acetylation exacerbate α-synuclein toxicity in vivo, in the substantia nigra of rats. Our study
identifies α-synuclein acetylation as a key regulatory mechanism governing α-synuclein
aggregation and toxicity, demonstrating the potential therapeutic value of sirtuin 2 inhibition
in synucleinopathies.
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Author summary
Parkinson disease is an age-associated neurodegenerative disorder characterized by the
loss of dopamine-producing neurons from a region in the brain known as the substantia
nigra and by the accumulation of the protein alpha-synuclein in intracellular clumps
called inclusions. Whether these inclusions are the cause or a consequence of the patho-
logical processes is still unclear. Sirtuin proteins are considered master regulators of the
ageing process and have previously been associated with neurodegeneration. In this study,
we investigated the interplay between sirtuin 2 and alpha-synuclein in order to dissect the
molecular mechanisms associated with protection against alpha-synuclein toxicity. We
found that sirtuin 2 interacted with and removed acetyl groups from alpha-synuclein. By
decreasing the levels of sirtuin 2, or by expressing mutant versions of alpha-synuclein that
modulate its acetylation status, we found that acetylation reduces the aggregation of
alpha-synuclein and its cytotoxicity in vitro. Next, we evaluated whether genetic inhibition
of sirtuin 2 could prevent the deleterious effects of alpha-synuclein in vivo and found that,
in two different models of Parkinson disease, deletion of sirtuin 2 was neuroprotective.
Our data therefore suggest that strategies aimed at decreasing sirtuin 2 activity might
prove valuable therapeutic avenues for intervention in Parkinson disease and other
synucleinopathies.
Introduction
Sirtuins are NAD+-dependent deacylases and lifespan determinants in several model organ-
isms. Sirtuin proteins have been implicated in neurodegenerative disorders, conditions that
are strongly associated with aging [1,2]. In mammals, there are seven members of the sirtuin
(SIRT) family: SIRT1–SIRT7. SIRT2 is the most abundant sirtuin in the brain and its levels
increase with aging [3]. Interestingly, SIRT2 emerged as a potential culprit in Parkinson dis-
ease (PD) pathology, as we showed that SIRT2 modulates α-synuclein (aSyn) aggregation and
toxicity [4]. Pharmacological inhibition of SIRT2 ameliorates aSyn-mediated toxicity in cell
models and in vivo (in a Drosophila model of PD), but the molecular mechanisms underlying
this effect remain unclear [4]. aSyn is the main constituent of Lewy bodies, protein inclusions
typically found in the brains of PD patients [5], and is therefore a central protein in PD. Inter-
estingly, the balance between acetylation and deacetylation is altered in both aging and neuro-
degeneration, and a link between acetylation of nonhistone proteins and neuroprotection has
recently emerged [6]. Given that SIRT2 is a deacetylase and that modulating its activity affects
aSyn aggregation and toxicity, we hypothesized that SIRT2 may induce neurodegeneration by
modulating aSyn acetylation, rendering it more prone to aggregate and to be cytotoxic. Here,
we provide detailed insight into the mechanism through which SIRT2 modulates aSyn toxicity
and demonstrate that acetylation on lysine (K)6 and K10 might be used as targets for therapeu-
tic intervention in PD and in other synucleinopathies.
Results
SIRT2 interacts with and deacetylates aSyn
To determine the mechanism of SIRT2-mediated protection against aSyn toxicity and aggrega-
tion, we hypothesized that aSyn might be acetylated and that this could be a substrate for
SIRT2. Thus, we first evaluated if aSyn was acetylated in mouse brain. To this purpose, endog-
enous aSyn was thermoenriched from the brain of wild-type (WT) mice and evaluated by
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mass spectrometry (MS) as we previously described [7]. Notably, we confirmed that aSyn is
ubiquitously acetylated at the N-terminus (Fig 1A and S1 Table) [8]. In addition, we identified
K6 and K10, in the conserved N-terminal region, as aSyn acetylation sites (Fig 1A and S1
Table). Next, we investigated whether SIRT2 and aSyn interact, as this would be an indication
that perhaps aSyn is a substrate for SIRT2. We coexpressed SIRT2 (tagged with green fluores-
cent protein [GFP]) with aSyn in human embryonic kidney (HEK) 293T cells and immuno-
precipitated aSyn or SIRT2. Using immunoblot analyses, we confirmed the
coimmunoprecipitation of aSyn with SIRT2, demonstrating that both proteins interacted (Fig
1B). To confirm the interaction in a physiologically relevant context (i.e., without overexpres-
sing the proteins), we immunoprecipitated aSyn from mouse brain extracts and, in agreement
with the results obtained in transfected HEK cells, we found that SIRT2 coimmunoprecipitated
with aSyn (Fig 1C).
Next, we investigated whether acetylated aSyn is a substrate of SIRT2 deacetylase activity.
We transiently expressed aSyn together with SIRT2 or with the enzymatically inactive SIRT2-
H187Y mutant in HEK cells and measured the levels of aSyn acetylation after immunoprecipi-
tation and immunoblotting with an anti-acetyl–lysine antibody. We found that SIRT2, but not
the inactive SIRT2-H187Y mutant, reduced the levels of acetylated aSyn (Fig 1D). We then
assessed the levels of aSyn acetylation in the brains of SIRT2 knockout (T2.KO) mice. Consis-
tently, we found that deletion of SIRT2 leads to aSyn hyperacetylation (Fig 1E and 1F). We
also observed an age-associated reduction in the levels of aSyn acetylation in T2.KO mice but
not in WT animals (S1 Fig).
To further investigate the ability of SIRT2 to deacetylate aSyn, we performed in vitro deace-
tylation assays. Chemical acetylation of aSyn yielded two to eight acetylations per protein mol-
ecule, with a distribution maximum of five acetyl modifications (Fig 1G). Peptide MS revealed
that three of the five KxK motifs in aSyn, namely K21/23, K32/34, and K58/60, showed little or
no acetylation, while all other lysines—including K6 and K10—were acetylated efficiently (Fig
1H, S2 Fig). In vitro treatment of acetylated aSyn with SIRT2 and NAD+, its cofactor, caused
efficient deacetylation, as demonstrated by the shift of the modification peak maximum from
five to two acetyl groups (Fig 1G). We also investigated the specific SIRT2-dependent deacety-
lation of aSyn on lysines K6 and K10. For this, we generated acetylated forms of aSyn specifi-
cally on residues K6 or K10 (acK6 and acK10) using our previously established semisynthetic
approach [9,10]. We found that SIRT2 indeed deacetylates both acK6 and acK10 in a dose-
dependent and in an NAD+-dependent manner, with similar efficiency (Fig 1I). In conclusion,
we identified K6 and K10 as aSyn acetylation sites that are targeted by SIRT2.
SIRT2 KD suppresses aSyn aggregation and toxicity
Given that we demonstrated that aSyn acetylation can be modulated by SIRT2, we investigated
whether SIRT2 modulates aSyn aggregation. To that purpose, we decreased SIRT2 levels using
short hairpin RNA (shRNA)-mediated knockdown in an established cellular model of PD in
which aSyn aggregation is recapitulated. This model consists of the coexpression of a C-termi-
nally modified form of aSyn (SynT) that increases its aggregation propensity, and synphilin-1
(an aSyn interactor that potentiates its aggregation) in H4 cells [11,12]. Upon SIRT2 knock-
down (T2.KD), we detected comparable levels of SynT and synphilin-1 as in cells transduced
with scramble shRNA (Scr) (Fig 2A). To quantify the effect on aSyn aggregation, T2.KD and
Scr cells were analyzed by immunocytochemistry (ICC) 48 h posttransfection. Remarkably,
T2.KD decreased the percentage of cells displaying SynT-positive inclusions to half of that in
control cells (Fig 2B). Biochemically, we confirmed that T2.KD increased SynT triton X-100
solubility (Fig 2C) and decreased the levels of higher-molecular-weight (MW) oligomeric
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PLOS Biology | DOI:10.1371/journal.pbio.2000374 March 3, 2017 3 / 27
enhanced GFP; GFP, green fluorescent protein;
HEK, human embryonic kidney cells; ICC,
immunocytochemistry; IP, immunoprecipitated;
LDH, lactate dehydrogenase; MAP2, microtubule-
associated protein 2; MS, mass spectrometry;
MW, molecular weight; NMR, nuclear magnetic
resonance; PD, Parkinson disease; Scr, scramble
shRNA; shRNA, short hairpin RNA; SIRT, sirtuin;
SN, substantia nigra; SUV, small unilamellar
vesicle; TH, tyrosine hydroxylase; ThT, thioflavin T;
T2.KD, SIRT2 knockdown; T2.KO, SIRT2 knockout;
WT, wild type.
Acetylation modulates a-synuclein toxicity
PLOS Biology | DOI:10.1371/journal.pbio.2000374 March 3, 2017 4 / 27
species, as assessed by sucrose gradient separation (Fig 2D). Next, we evaluated the levels of
acetylated aSyn in the same cell-based aggregation model. By immunoprecipitating SynT, we
observed that T2.KD increased the levels of acetylated aSyn (Fig 2E). Importantly, concomi-
tantly with the decrease in SynT aggregation and hyperacetylation, T2.KD also decreased the
cytotoxicity of SynT, as measured by the levels of lactate dehydrogenase (LDH) release from
cells (Fig 2F).
K6 and K10 acetylation modulate aSyn aggregation and membrane-
binding ability
To determine whether K6 and K10 acetylation modulated aSyn aggregation, we generated
aSyn mutants in which both lysine residues were replaced by either arginine residues (KR) to
mimic acetylation-resistant aSyn or by glutamine residues (KQ) to mimic constitutively acety-
lated aSyn [13]. Using the cell model of aSyn aggregation described above, we observed that
while the acetylation-resistant mutant KR promoted SynT aggregation, the acetylation mimic
mutant KQ prevented it (Fig 3A).
To assess if the observed phenotype was due to an intrinsic modulation of aSyn aggregation,
we investigated the oligomerization kinetics of recombinant mutant aSyn, as previously
described [14]. The kinetics of aSyn fibril formation was monitored using thioflavin T (ThT).
For the WT aSyn, we observed the expected increase in ThT fluorescence signal, confirming
the formation of amyloid-like fibrils (Fig 3B). Interestingly, we observed that while acetyla-
tion-resistant mutants increased, acetylation-mimic mutants prevented aSyn oligomerization
(Fig 3B). Moreover, when coincubated with WT aSyn, acetylation-resistant mutants also
increased, while acetylation-mimic mutants prevented WT aSyn oligomerization (Fig 3B).
We then investigated the effects of aSyn acetylation on its structure, using nuclear magnetic
resonance (NMR) spectroscopy, using again recombinant KR and KQ aSyn mutants produced
in Escherichia coli, as above. Two-dimensional 1H-15N correlation spectra of soluble aSyn and
its mutants showed a narrow spread of NMR resonances, demonstrating that both WT and
acetylation-resistant and/or acetylation-mimic mutants are intrinsically disordered (Fig 3C
and S3A Fig). In addition, a high degree of NMR signal overlap between the WT and mutant
Fig 1. SIRT2 interacts with aSyn and deacetylates lysine 6 and 10. (A) Detection of aSyn acetylation on
lysine 6 (K6) and lysine 10 (K10) by peptide mass fingerprinting analysis in total mouse brain lysates. Spectrum
shows acetylated peptides in red and aSyn peptides in blue. The corresponding peptide sequences are shown
(red residues are acetylated and green residues are oxidated). (B) Human HEK293T cells expressing the
indicated proteins were lysed and immunoprecipitated (IP) with anti-aSyn (left panels) or anti-SIRT2 polyclonal
antibodies (right panel). The whole-cell lysates (WCL) and immunoprecipitation samples were probed for GFP
(left panels) or aSyn (right panels). (C) Mouse whole-brain lysates (WBL) were lysed and IP with anti-aSyn
polyclonal antibody. The IP sample was probed with anti-SIRT2 and anti-aSyn. Rabbit IgG was used as a
negative control for the IP sample. (D) Immunoprecipitations were probed with an anti–acetyl-lysine antibody in
cells expressing either SIRT2 or the SIRT2-H187Y inactive mutant. (E) Immunoblot of thermoenriched aSyn
from mouse-brain lysate probed for acetyl-lysine and aSyn. (F) Brain protein extracts from WT and SIRT2
knockout (T2.KO) mice were separated by SDS-PAGE and immunoblotted with antibodies against acetyl-
lysine and aSyn (n = 3). The ratio of acetyl-lysine to aSyn is presented. *p < 0.05, unpaired t test with equal
standard deviation (SD). (G) Overlay of the deconvoluted intact protein mass spectra obtained from chemically
acetylated aSyn (theoretical mass 14,460 Da) in buffer (green) and treated with SIRT2 (purple). The observed
masses of the different species correlate with the presence of multiple acetyl modifications (+42 Da), ranging
from 2 to 8 before treatment with SIRT2 and from 0 to 6 after deacetylation with SIRT2. (H) Mass spectrometry
fragmentation analysis of a peptide from aSyn carrying acetylations at K6 and K10. Red peaks correspond to y-
ion series, green peaks to b-ion series, and purple peaks to a-ion series. Corresponding amino acids to mass
intervals of y-ion and b-ion series are represented (red and green, respectively). (I) Semisynthetic aSyn
acetylated at K6 and K10 were incubated with increasing amounts of recombinant SIRT2 in the presence or
absence of NAD at 37˚C for 3 h. Proteins were probed for acetyl-lysine residues, aSyn, and SIRT2. All images
are representative out of three independent experiments. Data in S1 Data.
doi:10.1371/journal.pbio.2000374.g001
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proteins suggested that the mutations do not strongly perturb the conformational ensemble of
aSyn in solution (Fig 3C and S3A Fig).
Next, we probed the impact of acetylation-resistant and acetylation-mimic mutants on the
ability of aSyn to bind to lipid membranes, a property thought to be associated with the physio-
logical function of the protein. In the presence of small unilamellar vesicles (SUVs), aSyn con-
stantly exchanges between the soluble disordered state and the helical, membrane-bound
structure [15]. Because of this exchange process, aSyn residues involved in membrane-binding
experience NMR line broadening [15], in which residues with stronger binding generally expe-
rience more broadening. We detected the residue-specific NMR signal attenuation, which is
typically observed for aSyn in the presence of SUVs: the N-terminal 100 residues are strongly
attenuated—in particular the N-terminal 20–30 residues, which anchor aSyn to the membrane
surface [16]—while the C-terminal domain of aSyn binds only very weakly to POPC:POPA
Fig 2. SIRT2 regulates aSyn aggregation and toxicity. (A) H4 cells were infected with lentiviruses encoding
shRNAs against SIRT2 (T2.KD) or scramble shRNA (Ctrl) and selected with puromycin. Cells were then
cotransfected with SynT and synphilin-1 (Synph1). SIRT2, synphilin-1, aSyn, and GAPDH levels were assessed
by immunoblot analyses. (B) Ctrl and T2.KD cells transiently expressing SynT and synphilin-1 for 48 h were
processed for immunocytochemistry (ICC) (aSyn, green). Data show percentage of cells with aSyn inclusions
(n = 3). Scale bar 15 μm. (C) Triton X-100 insoluble and total fractions of cells as in (B) probed for aSyn and
GAPDH. (D) Native protein extracts from H4 cells as in (B) were separated on a sucrose gradient. Fractions
were immunoblotted and probed for aSyn. (E) Anti-aSyn IP from cells as in (B). Fractions were immunoblotted
and probed for acetyl-lysine and aSyn. (F) Toxicity of Ctrl and T2.KD measured by lactate dehydrogenase (LDH)
release assay (n = 3). Data in all panels are average ±SD, ** p < 0.01, **** p < 0.0001. For (B) and (F),
unpaired, two-tailed t test with equal SD. Data in S1 Data.
doi:10.1371/journal.pbio.2000374.g002
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Fig 3. aSyn aggregation is modulated by acetylation. (A) H4 cells were cotransfected with WT, acetylation-resistant
mutants (K6R, K10R, K6+10R), or acetylation-mimicking mutants (K6Q, K10Q, K6+10Q) of SynT together with synphilin-
1. 48 h after transfection, cells were processed for ICC and the percentage of cells with inclusions was determined (n = 3).
Data in panels are average ± SD, **** p < 0.0001, ordinary one-way ANOVA with Tukey’s multiple comparisons test. (B)
Oligomerization kinetics of recombinant aSyn assessed by Thioflavin-T reaction. WT, K6+10Q, K6+10R, and a mixture of
1:1 of WT with K6+10Q or K6+10R were evaluated. (C) Superposition of 2D 1H-15N HSQC nuclear magnetic resonance
(NMR) spectra of recombinant 15N-labelled aSyn WT (black), K6+10Q (green). (D) Residue-specific changes in 1H-15N
HSQC signal intensities of aSyn WT (black) and aSyn K6+10Q (green) upon addition of small unilamellar vesicles (SUVs)
formed by POPC:POPA (1:1 molar ratio). The aSyn-to-lipid molar ratio was 1:100. (E) Estimation of the binding affinity of
aSyn to POPC:POPA SUVs from circular dichroism. Variations in absorption at 222 nm are plotted as a function of lipid:
protein molar ratio. Calculated affinities are 57 ± 13 and 71 ± 16 μM for aSyn WT (black) and aSyn K6+10Q (green),
respectively. Data in S1 Data.
doi:10.1371/journal.pbio.2000374.g003
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membranes (Fig 3D and S3B Fig). In the case of the acetylation-resistant mutant (aSyn KR), a
very similar profile was observed, demonstrating that replacement of lysine residues at posi-
tions 6 and 10 with arginine does not perturb the exchange of aSyn between the solution and
membrane-bound state (S3B Fig). In contrast, addition of POPC:POPA SUVs to the acetyla-
tion-mimic mutant (aSyn KQ) resulted in less signal attenuation, and thus higher NMR signal
intensities, in the N-terminal 100 residues when compared to the WT protein (Fig 3D). The
strongest difference was observed for the N-terminal 20–30 residues. Because of the dynamic
nature of the aSyn–membrane interaction, the overall affinity of aSyn for POPC:POPA mem-
branes was only slightly attenuated, as estimated by circular dichroism (Fig 3E).
aSyn acetylation modulates autophagy
Since T2.KD decreased SynT aggregation, we evaluated how it affected SynT clearance in the
cell. For this purpose, we performed a time-chase experiment blocking de novo protein syn-
thesis with cycloheximide (CHX). We did not observe significant differences in the levels of
SynT between T2.KD or Scr cells (Fig 4A). Since the autophagy lysosome pathway (ALP) is
described as the main mechanism to clear high-molecular-weight species of aSyn that cannot
be degraded by the proteasome [17], we evaluated the effects of T2.KD on autophagy. Remark-
ably, although we observed no differences in the ALP in naïve cells, T2.KD significantly
enhanced the activity of the ALP in the SynT aggregation model, as seen by the increased accu-
mulation of LC3-II levels after 2 h of ALP inhibition with bafilomycin A (Fig 4B). To further
evaluate these findings, we scored the number of LC3 punctae in T2.KD and Scr cells in both
naïve cells or in the SynT aggregation model using immunocytochemistry for LC3 (Fig 4C). In
agreement with the previous data, LC3 punctae were not modulated by T2.KD in naïve cells.
However, in the aSyn aggregation model, T2.KD increased the number of LC3 punctae per cell
(Fig 4C). Consistently, upon T2.KD, we observe a basal decrease in the levels of SQSTM1
(P62) in the cell model of aSyn aggregation (S4 Fig). In total, these results suggest that while
basal autophagy is not affected by SIRT2, upon aSyn aggregation, SIRT2 inhibition potentiates
the activity of ALP, thereby efficiently clearing aSyn aggregates.
aSyn acetylation is neuroprotective in primary cortical neurons
As we showed that SIRT2 regulates aSyn acetylation and that reduction of SIRT2 levels is pro-
tective in a cell model of PD, we next aimed at validating our findings in rat primary cortical
neuronal cells. It was previously described that 10 d posttransduction of primary cortical neu-
rons with adeno-associated viruses (AAV) encoding for WT aSyn results in severe neuronal
loss [18]. Based on this model, rat cortical neurons were transduced with AAV6 vectors encod-
ing WT, KR, or KQ aSyn under the synapsin promoter for neuronal expression (S5 Fig). We
detected similar expression levels of WT and of the two aSyn acetylation mutants 7 d post-viral
transduction (Fig 5A). Remarkably, we observed that cells expressing the acetylation-mimic
mutant (aSyn KQ) displayed a significant reduction in the toxicity observed 10 d posttransduc-
tion (31%) (S6 Fig). However, two to three weeks after transduction, no significant differences
were detected (S6 Fig). Next, we performed live cell imaging to determine the effect of aSyn
intrinsic acetylation in the number of living neurons over time. Neurons were cotransduced
with aSyn (WT or mutant) and enhanced GFP (EGFP), and EGFP-positive neurons were
counted at different time points (Fig 5B and 5C). At 7 d posttransduction, the number of trans-
duced neurons was identical for all conditions. Between 15 and 21 d posttransduction, both
WT and KR aSyn induced pronounced neuronal loss, while the number of living neurons in
cultures expressing the acetylation mimic mutant KQ was significantly higher (2-fold) (Fig 5B
and 5C). We next examined the distribution and intracellular localization of aSyn in neurons
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15 d posttransduction. Using an antibody that specifically recognizes human aSyn, we did not
observe major differences on the subcellular distribution of the different aSyn variants—all
were distributed throughout the neurons, both in cell bodies and neurites (Fig 5D). Strikingly,
both the WT and the KR aSyn severely affected the dendritic phenotype, promoting an evident
shortening and loss of dendritic arborisation (Fig 5D). In contrast, the dendritic structure was
preserved in neurons expressing the KQ mutant, as shown by microtubule-associated protein
2 (MAP2) staining (Fig 5D). Overall, both WT and KR—but not KQ aSyn—promoted
Fig 4. Acetylation of aSyn enhances the clearance of aSyn inclusions by autophagy. (A) H4 cells
(control and T2.KD) transiently expressing SynT and synphilin-1 were treated with cycloheximide (CHX)
for 4, 8, and 12 h. Protein extracts were then separated on SDS-PAGE and probed for aSyn and GAPDH
for normalization (at least n = 3). (B) Cells as in (A) were treated with bafilomycin A1 (BafA) for 2 and 4 h.
Protein extracts were probed for LC3 and β-actin. LC3-II levels were normalized to β-actin, and the
difference between BafA treatment for 2 h and vehicle (0 h) treatment was calculated (at least n = 3). (C)
Cells as in (A) were processed for ICC (LC3, green). Number of LC3 puncta per cell were counted (n = 3).
Data in all panels are average ± SD, * p < 0.05, ** p < 0.01. For (B) and (C), ordinary one-way ANOVA with
Tukey’s multiple comparisons test. Data in S1 Data.
doi:10.1371/journal.pbio.2000374.g004
Acetylation modulates a-synuclein toxicity
PLOS Biology | DOI:10.1371/journal.pbio.2000374 March 3, 2017 9 / 27
prominent neurodegeneration and loss of dendritic arborisation, suggesting aSyn acetylation
is protective.
Blocking aSyn acetylation induces nigral dopaminergic neuronal loss
In order to investigate the effect of aSyn acetylation in vivo, we stereotaxically injected AAV6
viruses driving the neuronal expression of WT, KR, or KQ mutant aSyn into the rat substantia
nigra (SN). First, we established the neurotoxicity of AAV6-mediated expression of WT aSyn
at three different time points (S5A and S5B Fig). We observed that 6 d after injection of WT
aSyn, no significant tyrosine hydroxylase (TH) loss was detected. However, 12 d postinjection,
the number of TH-positive cells was significantly reduced in comparison to that observed in
the GFP-injected group. No additional TH-cell loss was observed 18 d postinjection, indicating
the lesion did not increase between 12 and 18 d postinjection. As expected, the expression of
GFP did not induce TH-positive neuronal loss (S7A and S7B Fig).
Fig 5. aSyn acetylation mimic is neuroprotective in primary cortical neurons. (A) Cultured primary
neurons were transduced with AAVs encoding for EGFP, WT aSyn, KQ, or KR-mutant aSyn at day in vitro 3
(DIV3). Whole-cell lysates were analyzed by immunoblotting 7 d postinfection with antibodies against aSyn and
β-actin (n = 3). (B) Primary neuronal cells were coinfected with aSyn and EGFP at DIV3 and monitored over
time. 16 images per condition were acquired, and the EGFP fluorescence signal was recorded in living neurons
at 7, 10, 15, 18, and 21 d posttransduction (n = 3). Representative images are shown. Scale bar 20 μm. (C)
Total number of EGFP positive cells normalized to the number of neurons on WT 7 d posttransduction is
presented (n = 6). Data in all panels are average ± SD, * p < 0.05, ** p < 0.01, *** p < 0.001, two-way ANOVA
with Bonferroni post-test. (D) Cortical neuronal cells 15 d posttransduction were processed for ICC (aSyn, red;
microtubule-associated protein 2 [MAP2], green; nuclei, Hoechst, blue). Representative images are presented.
Scale bar 200 μm. Data in S1 Data.
doi:10.1371/journal.pbio.2000374.g005
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Next, we compared the neurotoxicity of the KQ and KR aSyn mutants using the same para-
digm. Based on the data obtained for WT aSyn, we assessed the effect 3 wk postinjection. Ste-
reological quantification of TH-positive cells revealed a significant loss of TH-positive neurons
3 wk post-KR aSyn expression (Fig 6A and 6B). In agreement with the in vitro results, the TH-
positive cell loss in cells expressing the KQ aSyn mutant was identical to that observed in con-
trol conditions (GFP expression) (Fig 6B). On the other hand, the KR mutant induced strong
loss of TH-positive cells in the SN.
We next investigated whether interfering with aSyn acetylation on K6 and K10 affected
aSyn pathology in vivo. The expression of both KQ and KR aSyn variants in the SN resulted in
the detection of phosphorylated aSyn on Ser129 (pS129) (Fig 6C), suggesting the accumulation
of pathological forms of aSyn. However, the subcellular localization of the pS129 signal was dif-
ferent depending on the aSyn variant. While the KQ mutant displayed a predominantly cyto-
plasmic staining, the KR mutant displayed a homogeneous pS129 staining throughout the cells
(Fig 6C). We also assessed aSyn pathology by immunostaining with the 5G4 antibody, which
reacts with aggregated forms of aSyn [19] (S8 Fig). As expected, all variants tested resulted in
immunostaining with this antibody, suggesting they all formed aSyn aggregates. Unexpectedly,
we observed a stronger staining in rats expressing WT aSyn when compared to that observed
in animals expressing the acetylation mutants (S8A Fig). However, as observed for the pS129
staining, immunostaining with the 5G4 antibody also revealed different aSyn subcellular local-
ization depending on the mutant expressed. The KQ mutant appeared predominantly in the
cytoplasm, being excluded from the nucleus in most cells. In contrast, the signal for both KR
mutant or WT aSyn was homogeneously distributed throughout the cells (S8B Fig).
SIRT2 deletion protects from aSyn or MPTP toxicity in vivo
We showed that the levels of acetylated aSyn were increased in T2.KO mice (Fig 1E and 1F).
Next, to assess the effect of SIRT2 on aSyn-mediated neurodegeneration in vivo, we evaluated
whether deletion of SIRT2 protected against TH-cell loss. We stereotaxically injected AAV6
virus driving the neuronal expression of WT aSyn into the SN of WT or T2.KO mice. 2 wk
after viral injection, TH neuronal loss was observed in WT mice (28.5 ± 2.4% surviving neu-
rons). Remarkably, in T2.KO mice, we observed a clear protection (62.8 ± 5.5% surviving neu-
rons) (Fig 7A and 7B).
We further investigated the protective effects of SIRT2 deletion in the chronic MPTP
mouse model of parkinsonism [20]. As expected, 2 wk post-MPTP injection, we observed a
significant decrease in the percentage of TH neurons in WT mice (Fig 7C–7E). Overall neuro-
nal loss was also observed (Fig 7F). In contrast, we observed no neuronal loss in T2.KO ani-
mals (neither TH or overall neurons) (Fig 7C–7F).
Discussion
Aging is, by far, the major risk factor for PD and other neurodegenerative disorders, but the
precise molecular mechanisms involved are still elusive. The sirtuin family of deacetylases reg-
ulates many aspects of the aging process. Intriguingly, several sirtuins have emerged as putative
therapeutic targets in several neurodegenerative diseases. For example, SIRT1 overexpression
has proven beneficial in models of Alzheimer disease, Huntington disease, and PD [1,21].
However, while SIRT1 is ubiquitously expressed in the body, SIRT2 is the most abundant sir-
tuin in the brain and is primarily present in the cytoplasm of brain cells (neurons and oligo-
dendrocytes). The levels of SIRT2 increase with aging [3], and we previously showed that
pharmacological inhibition of this sirtuin is protective in cellular, Drosophila, and mouse mod-
els of PD but not in models of amyotrophic lateral sclerosis [4,22]. Nevertheless, the precise
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Fig 6. aSyn acetylation-resistant mutant induces nigral dopaminergic neuronal loss in vivo. (A)
AAV6-mediated delivery of EGFP and mutant aSyn (KQ or KR) into the SN of the rat brain. TH and GFP
or aSyn expression was examined in brain sections 3 wk after injection by immunohistochemistry (TH,
red; GFP or aSyn, green; DAPI, blue). Representative sections are shown. Scale bar for isolated
channels 1,000 μm and for merged channels 500 μm. (B) Stereological counting of the number of TH-
positive neurons in the SN. The contralateral SN of the different groups of animals was used as a control
(intact). Data in panels are average ± SD. (C) Brain sections stained for aSyn (green), pS129 aSyn (red),
and DAPI (Blue). Representative sections are shown. Dashed square boxes delineate the magnification
presented on the right. Scale bar for isolated channels 1,000 μm and for merged channels 500 μm and
50 μm. *** p < 0.001, **** p < 0.0001, one-way ANOVA with Bonferroni correction used for statistical
calculations. In (B), GFP was used as a control; n = 6–7 animals per condition; five sections from a one-
in-six series were analyzed per brain. Data in S1 Data.
doi:10.1371/journal.pbio.2000374.g006
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Fig 7. Knockout of SIRT2 protects from aSyn or MPTP toxicity in mice. (A) AAV6-mediated delivery of GFP
or WT aSyn into the SN of WT or T2.KO mice brains. TH and GFP or aSyn expression was examined in brain
sections 2 wk postinjection by immunohistochemistry (TH, red; GFP or aSyn, green; DAPI, blue). Representative
sections are shown. Scale bar for isolated channels 1,000 μm and for merged channels 500 μm. (B) Stereological
counting of the number of TH-positive neurons in the SN. The number of TH-positive neurons in the SN of GFP-
injected mice was used as control (at least n = 3 per group). Data, presented as percentage of TH-neurons, are
average ±SD. *** p < 0.001, unpaired t test with equal SD. Chronic MPTP treatment of WT or T2.KO mice brain.
TH (C) or neurons (Nissl) (D) were examined in brain sections 2 wk postinjection by immunohistochemistry (TH,
DAB; Neurons, Nissl; DAPI, blue). Representative sections are shown. Scale bar 200 μm. Stereological counting
of the number of TH-positive (E) or Nissl-positive neurons (F) in the SN (at least n = 4 per group). Neuron numbers
Acetylation modulates a-synuclein toxicity
PLOS Biology | DOI:10.1371/journal.pbio.2000374 March 3, 2017 13 / 27
mechanisms of SIRT2-mediated protection against aSyn aggregation and toxicity are still
unclear.
In the present study, we provide strong evidence demonstrating that SIRT2 inhibition
robustly alleviates neuropathology in several models of synucleinopathy by regulating the lev-
els of aSyn acetylation. We show, for the first time, that SIRT2 interacts with and deacetylates
aSyn in the highly conserved N-terminal domain.
We started with the premise that acetylation balance is impaired in neurodegeneration.
Thus, we first hypothesized that SIRT2-dependent modulation of aSyn acetylation could be
the basis for aSyn pathogenicity. It was previously shown that aSyn is acetylated in the N-ter-
minus [8,23] and that this modification is important for the interaction of aSyn with lipids, as
acetylation increases membrane-binding properties of aSyn by increasing its alpha helical con-
tent and reducing its ability to aggregate [24]. Other posttranslational modifications are also
known to affect the structure, membrane-binding ability, and oligomerization properties of
aSyn [25]. Since aSyn is a very lysine-rich protein, with 15 putative acetylation sites located
mainly in the N-terminal region of the protein [26], it was reasonable to hypothesize that aSyn
could be naturally acetylated in lysine residues in addition to the N-terminal acetylation and
that these residues could, perhaps, be substrates for SIRT2 deacetylation. In our study, and in
agreement with previous findings, we confirmed that aSyn is acetylated in the N-terminus.
However, we also detected acetylation on residues K6 and K10 (Fig 1A and S1 Table). Impor-
tantly, a previous proteomic analysis of lysine acetylation in rat tissue also detected aSyn acety-
lation on K6 [27]. Here, we also demonstrated that SIRT2 interacts with and deacetylates aSyn.
We previously reported that pharmacological inhibition of SIRT2 reduces aSyn toxicity and
decreases aggregation [4]. Therefore, to exclude potential off-target effects of SIRT2 inhibitors,
we evaluated the effects of genetic inhibition of SIRT2 on aSyn aggregation and toxicity in a
well-established cellular model of aSyn aggregation. Strikingly, we found that by elevating the
levels of aSyn acetylation, knockdown of SIRT2 was able to reduce aSyn aggregation and toxic-
ity. Therefore, we reasoned that aSyn acetylation might be protective. To evaluate the intrinsic
implications of aSyn acetylation on K6 and K10, we generated acetylation-mimic (KQ) and
acetylation-resistant (KR) mutants. Using the cell-based model of aSyn aggregation, we con-
firmed that while the majority of cells expressing the KR mutant displayed aSyn inclusions,
those expressing the KQ displayed almost no inclusions. Moreover, we showed that recombi-
nant aSyn acetylation mutants display the same trend. Notably, combining WT aSyn with the
KQ acetylation-mimic aSyn suppressed fibrillisation, while combining WT with the KR acety-
lation-resistant mutant potentiated aSyn fibrillisation.
The fact that KQ aSyn is able to suppress WT aSyn fibrillisation suggests that, in normal con-
ditions, the acetylated form of aSyn might be dominant. This observation raises the important
and provocative question of how much acetylated aSyn is necessary in the brain in order to pre-
vent fibrillisation as we age. Going one step further, this might enable us to predict what are the
chances of developing PD later in life by measuring the levels of SIRT2 and/or acetylated aSyn
and could shed light into the question of why some people end up developing PD later in life.
Both NMR and far UV-CD data showed that the presence of acetylation-resistant modifica-
tions do not affect the binding of aSyn to lipid vesicles (S3A Fig). In contrast, mimicking aSyn
acetylation reduces the ability of the N-terminal region to bind membranes, preventing this
in NaCl-injected mice were used as normalization controls, and data are expressed as percentage of the
corresponding NaCl-injected control animals. For (E) and (F), data (presented as percentage of neurons), are
average ±SD. * p < 0.05, ** p < 0.01, two-way ANOVA followed by Tukey’s multiple comparisons test. Data in S1
Data.
doi:10.1371/journal.pbio.2000374.g007
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region from acting as a membrane-attachment anchor (Fig 3D and 3E). Importantly, this find-
ing suggests that acetylation may regulate the physiological role of aSyn on vesicular trafficking
[28,29] and should be further investigated in future studies.
Protein acetylation is known to modulate the clearance of different proteins. For example,
acetylation of huntingtin—another intrinsically disordered and misfolding-prone protein—on
K444 facilitates its clearance via the ALP [30]. In addition, SIRT2 has been previously associ-
ated with autophagy. First, when SIRT2 releases FOXO1, the latter gets acetylated and binds to
ATG7, inducing autophagy in the context of cancer [31,32]. Second, overexpression of SIRT2
inhibits autophagic turnover by interfering with aggresome formation [33]. Therefore, we
asked whether SIRT2 could also modulate the clearance of aSyn, mainly by interfering with
the ALP. Although we did not observe significant differences in the rate of aSyn clearance, we
found that T2.KD induced macroautophagy only in the presence of aSyn inclusions (Fig 4B
and 4C and S4 Fig). Since we observed that acetylated aSyn is less prone to aggregate and
could even prevent the aggregation of the WT form and that T2.KD promoted a more efficient
clearance of the aggregates, we propose that SIRT2 acts on several fronts, potentiating neuro-
degeneration. On one side, SIRT2 affects the conformation of aSyn through deacetylation,
thus rendering it more prone to aggregate. Simultaneously, it regulates the main clearance
pathway for aggregated aSyn. Therefore, we propose a model in which the age-dependent
increase of SIRT2 in the brain, with the concomitant decrease of acetylated aSyn, comes with
two major deleterious consequences: an increase of aggregation and the exacerbation of the
expected defects in the ALP associated with aging [34].
We then assessed the effects of aSyn acetylation in rat primary cortical cultures. By analysing
the expression of aSyn acetylation mutants over time, we observed that while expression of the
acetylation-resistant mutant aSyn induced a similar reduction in the number of neurons to that
observed for WT aSyn, the acetylation-mimic mutant was less toxic. Expression of the same
aSyn variants in vivo in the rat SN confirmed that the acetylation-mimic KQ mutant was less
toxic to TH-positive neurons that the KR mutant or than WT aSyn. Interestingly, although the
immunoreactivity for pS129 or aggregated forms of aSyn was identical for both the KQ and KR
mutants, the intracellular distribution of the protein was altered. Altogether, this suggests that
acetylation may not completely abolish the ability of aSyn to aggregate in vivo but that it may
also modulate the subcellular distribution of the protein, thereby modulating its toxicity.
Given the protective effects of mimicking aSyn acetylation in vivo, we also evaluated the
putative protective effects of SIRT2 deletion. For this we used two in vivo models reporting on
different aspects of PD: aSyn toxicity and TH-cell loss. Importantly, we found that SIRT2 dele-
tion was protective in both the AAV-mediated model of aSyn expression in the SN and in the
chronic MPTP model of parkinsonism.
In summary, our data suggest that acetylation of aSyn on K6 and K10 may regulate the dis-
tribution (and perhaps the function) of aSyn, also modulating its aggregation potential and
toxicity. We identify acetylation as a mechanism for removing aSyn by targeting it to autop-
hagy. Thus, SIRT2 activity is an important mediator of aSyn acetylation, underlying its poten-
tial as a target for therapeutic intervention in synucleinopathies and, possibly, in other
neurodegenerative disorders in which protein acetylation may play underappreciated roles in
modulating protein homeostasis.
Materials and methods
Ethics statement
This study does not involve human participants or tissue. All experimental animal procedures
were conducted according to approved experimental animal licenses, issued by the responsible
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animal welfare authority (Niedersa¨chsisches Landesamt fu¨r Verbraucherschutz und Lebens-
mittelsicherheit) and controlled by the local animal welfare committee and veterinarians at the
University Medical Center Go¨ttingen after approval from the ethics committee.
Mass spectrometry analysis
Total protein extracts from C57Bl/6 mice brain samples were processed as in [7]. Mass spec-
trometry was performed on an Applied Biosystems 4700 Proteomics Analyzer with TOF/TOF
ion optics as previously described [7]. All peptide mass values were considered monoisotopic,
and a MS mass tolerance was set at 100 ppm. Trypsin was assigned as digestion enzyme of
aSyn. A triple miss cleavage was allowed and oxidation of methionyl residues, acetylation of
the N-terminus, and acetylation of lysine residues were assumed as variable modifications. All
peaks with S/N greater than 5 were included for matching against in silico digestion of corre-
sponding aSyn sequence (Mus muscullus) in mMass software [35].
H4 and HEK 293T cell culture and transfection
Cells were cultured at 37˚C in a humidified incubator containing 5% CO2 (g). H4 cells were
grown in Opti-MEM medium (Gibco-Invitrogen), and HEK 293T cells were grown in DMEM
with GlutaMax medium (Gibco-Invitrogen); both were supplemented with fetal bovine serum
(FBS) (10% v/v). Cells were transfected with FuGENE 6 transfection Reagent (Roche) as previ-
ously described [7]. Briefly, 293T cells were transfected with GFP or SIRT2 fused with GFP
(SIRT2::GFP) or cotransfected with GFP with aSyn or SIRT2::GFP with aSyn.
Immunoprecipitation
Protein immunoprecipitation was performed as we previously described [36].
Immunoblotting
Cells lysis and immunoblotting was performed as previously described [7]. For immunoblot-
ting, we used the following antibodies: anti-aSyn (BD Transduction laboratories, S63320,
1:3000), anti-V5 (Santa Cruz, SC-83849-R, 1:1000), anti-LC3 (Nano Tools, 0260-100/LC3-
2G6, 1:2000), anti–β-actin (Ambion, AM4302, 1:5000), anti-GAPDH (Ambion, AM4300,
1:5000), anti-GFP (NeuroMab, P42212, 1:3000), and anti–acetyl-lysine (Cell Signaling, 9441S,
1:1000).
Plasmids for aSyn recombinant protein expression
aSyn double mutants were generated by site-directed mutagenesis to mimic the acetylated or
the nonacetylated forms of aSyn, replacing the lysine on positions 6 and 10 by glutamine (K6
+ 10Q = KQ) or arginine (K6 + 10R = KR), respectively.
Acetylation studies in mice
Animal experiments were performed according to institutional and national regulations. All
mice used were in congenic C57Bl/6. SIRT2 knockout mice have been described previously
[37]. All mice were housed at controlled temperature (25˚C) and 12:12 h light/dark cycle. For
protein analysis, brains from mice at the different ages (2 and 8 mo old) were quickly removed,
striata were dissected, and samples were homogenized in RIPA buffer in the presence of prote-
ase and phosphatase inhibitors (Roche Complete and PhosStop). Samples were then rotated
for 1 h at 4˚C and centrifuged at 18,000 g for 30 min. For further analyses, we used the soluble
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fractions. aSyn was partially purified and enriched as described in [7]. For immunoblotting,
we used anti aSyn and antiacetylated lysine antibodies.
Recombinant Sirt2 production
Recombinant SIRT2 (43–356) was expressed in E. coli and purified through affinity and size-
exclusion chromatography as previously described in [38].
Chemical acetylation and enzymatic deacetylation
The buffer of aSyn was exchanged to 100 mM sodium phosphate pH 7.4 using a NAP-5 col-
umn (GE Healthcare). aSyn was subsequently treated with acetic anhydride, 13 mM final con-
centration (10-fold molar excess compared to the lysine concentration), by four consecutive,
stepwise additions over an hour followed by an extra hour of incubation on ice. Excess acetic
anhydride was then quenched by addition of 20 mM Tris pH 8.0.
For the enzymatic deacetylation, 1.1 μM chemically acetylated aSyn was incubated for 1 h
on ice in the presence or absence of 0.11 μM SIRT2 and 1 mM NAD+, and intact protein mas-
ses were then determined through HPLC-coupled ESI-MS. Proteins were concentrated and
washed on a Piccolo Proto 200 C4 5μm 2.5 x 0.5mm trap column (Higgins Analytical, Moun-
tain View, California) and subsequently switched in line with and separated on a Jupiter C4
5μm 300Å 150 x 1 mm analytical column (Phenomenex, Torrance, California) mounted onto
a Shimadzu Prominence UFLC (Shimadzu, Duisburg, Germany) at a 70μl min-1 flow rate with
the following buffers: A—5% ACN, 5% DMSO, and 0.1% FA; B—90% ACN, 5% DMSO, and
0.1% FA. Proteins were then eluted over with a gradient of 3 min of 1% B to 55% B followed by
1 min of 55% B to 90% B. Mass analysis was performed by ESI-TOF-MS on an AB Sciex Tri-
pleTOF 5600+ mass spectrometer (Sciex, Darmstadt, Germany) with a DuoSpray Ion Source
with the following settings: floating voltage of 5,500 V, temperature of 350˚C, and declustering
potential of 120 with 4 separate TOF experiments each, respectively, with 4, 12, 20, and 40
time bins summed. Spectra were integrated over a retention time period, and the summed
TOF experiment with the greatest resolution was selected. The raw data was then converted
and deconvoluted using the MaxEnt I algorithm (Waters, Milford, Massachusetts) at a resolu-
tion of 0.1 Da.
In vitro deacetylation of semisynthetic acK6 and acK10
Chemical acetylated aSyn at lysine 6 (acK6) or 10 (acK10) was obtained by using the semisyn-
thetic approach [9,10]. acK6 or acK10 was incubated in the presence or absence of both recom-
binant SIRT2 in increasing amounts and NAD+ (1 mM) at 37˚C in SDAC buffer (50 mM
TrisHCl [pH 9.0], 4 mM MgCl2, 50 mM NaCl, 0.5 mM DTT). 3 h postincubation, the reaction
was stopped by the addition of protein sample buffer.
Viral production and infections of SIRT2 shRNA
HEK 293T cells (1.5 x 10⁶) were cotransfected with Δ8.9, VSVG, and SIRT2 shRNA plasmids
(1.8μg, 0.2μg, and 2μg, respectively—Sigma RNAi facility) using FuGENE6 (Promega, Wis-
consin, United States). 48 h posttransfection, the lentiviruses were collected and filtered
(0.45μm). H4 cells (1 x 105) were infected with the lentivirus supplemented with PolyBrene
(10μg/mL) (Sigma). After 4 h, medium was replaced by Opti-MEM supplemented with FBS.
48 h postinfection, cells were selected using Puromycin-Dihydrochloride (1μg/mL; Sigma).
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aSyn aggregation model of human cells
The aggregation model of H4 neuroglioma cells was used as previously [36]. Immunocyto-
chemistry was performed as previously [36].
Sucrose gradient
Total protein from Scr or T2.KD H4 cells transiently expressing SynT with synphilin-1 was
processed on a 5% to 30% sucrose gradient as previously described [39].
Triton insolubility assay
Total protein (500 μg) from Scr or T2.KD cells transiently expressing SynT and synphilin-1 for
48 h was incubated with 1% Triton X-100 on ice for 30 min. Protein fractions were separated
by centrifugation at 15,000 g for 60 min at 4˚C. Soluble protein fraction was collected and the
insoluble protein fraction pellet was resuspended in 40 μL of 2% SDS Tris-HCl buffer pH 7.4
and sonicated for 10 s. Total protein and T-Insoluble fractions (5 μl of each) were loaded and
resolved by SDS-PAGE and immunoblotted as previously described.
LDH cytotoxicity assays in H4 cells
Cytotoxicity was measured using LDH kit (Clontech) as previously described [14].
Recombinant aSyn aggregation assay
The expression and purification of human aSyn was performed as previously described [7].
aSyn aggregation assay was performed as previously described [14]. WT and acetylation
mutants K6+10Q or K6+10R were combined in a 1:1 ratio.
NMR spectroscopy
1H-15N HSQC spectra of 15N-labelled wild-type and acetylation mutants K6+10Q or K6+10R
aSyn were acquired at 15˚C on a 600 MHz Bruker spectrometer in HEPES 25 mM, pH 7.0,
NaCl 50 mM, 10% D2O. aSyn backbone resonance assignment was transferred from previous
studies [40]. In case of K6+10Q or K6+10R aSyn, peak centers were adjusted only in regions of
small signal overlap. Peaks affected by severe overlap were excluded from the analysis. NMR
data were processed and analyzed by using NMRPipe [41] and Sparky (T. D. Goddard and D.
G. Kneller, University of California, San Francisco).
For NMR and CD measurements (see below) of aSyn in the presence of SUVs, SUVs were
prepared with 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) and 1-palmitoyl-
2-oleoyl-sn-glycero-3-phosphate (POPA) (Avanti Polar Lipids) at a 1:1 molar ratio using pre-
viously published protocols [42].
Circular dichroism
Far UV-CD measurements were performed on a Chirascan (Applied Photophysics, United
Kingdom) circular dichroism spectrometer using protein concentrations of 10 μM in HEPES
buffer, 10 mM NaCl, pH 7.4, in a quartz cuvette with a 0.1 cm light-path. To probe the binding
of aSyn to SUVs, increasing concentrations of SUVs were added (from 1:20 to 1:270 protein-
to-lipid molar ratio). Each experiment was repeated at least twice. Baseline correction was per-
formed with the same buffer. Data were expressed as mean residue ellipticity (degree cm2
dmol –1). Affinity curves were fitted with a single exponential equation considering a one site–
specific binding model.
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aSyn clearance
For CHX chase experiments, Scr or T2.KD H4 cells were transfected with SynT as previously
[7]. 40 h posttransfection, cells were treated with cycloheximide (100 μM, added at given time
points). Protein extracts were immunoblotted. Autophagy activity studies were performed as
previously described [43]. Activity was given by the amount of accumulated LC3 after 2 h of
treatment with the autophagy blocker bafilomycin A. Basal levels of SQSTM1 (p62) were also
measured (sc-28359, Santa Cruz Biotechnology). For LC3 punctae analysis, 1.2 x 105 cells were
seeded on MatTek dishes. 48 h after plating, cells were carefully washed three times with PBS
and processed for immunocytochemistry, as previously described [36], using an anti-LC3 anti-
body. Fluorescence was detected by the use of a widefield fluorescence microscope or a confo-
cal microscope. The number of LC3 punctae per cell was determined.
Generation of plasmids for the production of adeno-associated viruses
(AAV)
For the generation of the AAV vectors of serotype 6 (AAV-6) constructs encoding for human
WT aSyn and lysine mutants (K6+10Q and K6+10R), cDNA was amplified by PCR using the
following primers: Forward Primer sequence for WT aSyn: 50- GGCAGATCTACCGGTCGC-
CACCATGGATGTATTCATGAAAGGACTTTCAA AGGCCAAGGAGGG -30; Forward
Primer sequence for K6+10Q aSyn mutant: 50- GGCAGATCTACC GGTCGCCACCATG-
GATGTATTCATGCAGGGACTTTCACAGGCCAAGGAGGGA -30; Forward Primer
sequence for K6+10R aSyn mutant: 50- GGCAGATCTACCGGTCGCCACCATGGATG-
TATTCATGAGAG GACTTTCAAGGGCCAAGGAGGGA -30; Reverse Primer sequence for
aSyn WT sequence: 50-CCCGC GGCCGCTTAGGCTTCAGGTTCGTAGTCTT -30. PCR
products were digested with restriction enzymes and cloned into pAAV-6P-SEWB.
AAV vector preparation
WT and mutated aSyn was expressed from human synapsin-1 (hSyn1) gene promoters, fol-
lowed by WPRE and bovine growth hormone polyadenylation site according to standard pro-
cedures (S2 Fig) [44]. Briefly, recombinant AAV-6 for expression of WT, KQ (K6+10Q), or
KR (K6+10R) were produced by transient transfection in HEK293 cells, purified by iodixanol
gradient ultracentrifugation and heparin affinity chromatography, and dialysed against PBS.
Vector titres were determined by qPCR, and purity of viral particles was confirmed to be
>98% by SDS-PAGE. Vector titres were 5 x 10e12 vg/ml for WT and K6/10R synuclein and 8
x 10e12 vg/ml for K6/10Q synuclein.
Primary cell culture
Primary cortical cultures were prepared from Wistar rats at embryonic day 18, as previously
described [45]. Cortical cells were seeded in poly-ornithine (PLO) precoated glass coverslips
(13 mm) at a density of 250,000 cells/well, and were maintained in Neurobasal medium
(Gibco) supplemented with 1% Penicillin-Streptomycin (Pan-Biotech), 0.5 mg/mL Transferrin
(Sigma), 125mM L-glutamine (Pan-Biotech), and 1 x B27 (Gibco). Cultures were grown at
37˚C in humidified 5% CO2 atmosphere. At DIV3, neuronal cells were infected with equimo-
lar amounts of recombinant adeno-associated virus (AAV-6), under the synapsin promoter,
encoding for EGFP, WT, or mutant aSyn (1 x 108 vg/250,000 neurons/well). For live cell imag-
ing experiments, cells were cotransduced with 1 x 104 vg EGFP/250,000 neurons/well.
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Live cell imaging
Transduced cells were imaged on an Olympus IX81-ZDC microscope system (Olympus) with
a 10x objective. An EGFP fluorescence signal was recorded with constant exposure time (300
ms) from living neurons at 7, 10, 15, 18, and 21 d posttransduction. A total of 16 images per
well were randomly and automatically collected for quantification analysis. The total number
of GFP-positive cells was counted for each condition using the Olympus Scan R Image Analy-
sis Software and normalized to EGFP + WT aSyn.
Primary cultures toxicity measurements
Supernatants were collected from primary cells on 10, 15, and 18 d posttransduction. Cell via-
bility was assessed by quantitatively measuring LDH as previously mentioned. For background
control, noninfected cultures were used, and maximal LDH release was measured in the super-
natants of primary cells lysed with 2% Triton X-100. Percentage of toxicity was calculated as
indicated by the manufacturer.
Cortical neurons immunohistochemistry
Cortical primary cells growing on glass coverslips were fixed for 10 min with 4% paraformal-
dehyde 15 d after transduction. Following three washes with PBS, cells were permeabilized for
15 min with 0.5% Triton/PBS and blocked with 3% BSA/PBS for 1 h at room temperature
(RT). Human anti-aSyn antibody (MJFR1, abcam #ab138501) and anti-MAP2 (Sigma
#M9942) were prepared 1:1,000 in blocking solution and incubated overnight, at 4˚C. Cover-
slips were carefully washed three times with PBS and incubated with secondary Alexa Fluor
antibodies (Life Technologies) diluted 1:1,000 in blocking buffer at RT. Nuclei were stained
with Hoechst, and after three washes with PBS, coverslips were embedded in moviol. Imaging
was performed using an epifluorescence microscope (Leica DMI 6000B microscope, Leica).
Stereotaxic injections in rats
Young adult female Wistar rats (230–260g each; Janvier, Saint Berthevin, France) were used
for AAV injections. Rats were housed in a temperature-controlled room that was maintained
on a 12-h light and/or dark cycle. Food and water were provided ad libitum.
Stereotaxic injections in the rat SN
All surgical procedures, intracerebral stereotaxic vector injections into the right hemisphere
SNpc (coordinates were as follows: AP: –4.7; ML: –2.2; DV: –7.6 mm relative to Bregma, tooth
bar: –3.3 mm) (S3C Fig), and tissue preparations were performed essentially as described [18].
In a first attempt, young adult female Wistar rats (230–260g) were injected with 2 μL of
control GFP or human WT aSyn AAV6 virus (~1x108 vector genomes [vg]/ml) into the right
SN at a flow rate of 0.2 μl/min. Animals were PFA-perfused 1, 2, and 3 wk after virus injection.
In a second attempt, young adult female Wistar rats (230–260g) were injected with 2 μL of
control GFP, human WT, or mutants KR and KR aSyn AAV6 virus (~1x108 vg/ml) into the
right SN at a flow rate of 0.2 μl/min. Animals were PFA-perfused 3 wk after virus injection. 40-
μm thick serial coronal sections from the SN were collected on a cryostat (Leica) and processed
for immunohistochemistry stainings.
Immunohistochemistry of rat brain sections
Rat tissue preparation. Rats were transcardially perfused with 150 ml in phosphate buffer
(PB) followed by 150 ml 4% PFA in PB at a flow rate of 15 ml/min. The brains of the animals
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were removed, postfixed overnight in the same solution, then cryoprotected by immersion in
30% sucrose for 36 h. Free-floating 40 μm serial coronal sections from throughout the SN were
collected with a Cryostat (Leica Microsystems, Germany). Brain slices were placed in a storage
solution (30% glycerol, 30% ethylene glycol in 0.1 M PB) and stored at –20˚C before use.
Fluorescent stainings. For the detection of fluorescent proteins after infection, free-float-
ing sections were washed three times in phosphate-buffered saline (PBS), blocked in PBS con-
taining 4.5% bovine saline albumin (BSA) for 1 h, then incubated overnight at 4˚C in PBS
containing 3% BSA, 0.2% Triton X-100, and one of the following antibodies of interest. Sec-
tions were rinsed three times in PBS and incubated with Alexa Fluor 488-labeled antimouse or
rabbit IgG or Alexa Fluor 555-labeled antimouse or rabbit IgG (Invitrogen) at room tempera-
ture for 1 h. The sections were rinsed in PBS and the nuclei were counterstained with DAPI
(dilution 1:10,000, Wako) for 3 min. The sections were mounted in Mowiol.
Series of sections were stained for aSyn to localize the injection site in aSyn-injected rats.
Tyrosine hydroxylase (TH) (Rabbit, Millipore, ab152) immunostaining was used in order to
quantify the loss of dopaminergic neurons in the injected rats. The following antibodies were
used to detect specific synucleins: N-terminal rat aSyn (Mouse, Bd Transduction Laboratories,
610787), recognized amino acid 121–125 of human aSyn (Mouse, Santa-Cruz, SC-12767),
pS129 aSyn (Rabbit, Abcam, ab51253), and aggregated forms of aSyn (Mouse, Millipore, clone
5G4, MABN389).
Stereotaxic injections in the SN
Mice were housed in a temperature-controlled room that was maintained on a 12 h light and/
or dark cycle. Food and water were available ad libitum. Both female and male WT and
SIRT2-KO mice were used for AAV injections. All surgical procedures, intracerebral stereo-
taxic vector injections into the right hemisphere SNpc (coordinates were as follows: AP: –3.2;
ML: –1.2; DV: –4.4 mm relative to Bregma, tooth bar: 0.0 mm), and tissue preparations were
performed essentially as described [46]. Mice were injected with 2 μL of control GFP or
human WT aSyn AAV6 virus (~1x108 vg/ml) into the right SN at a flow rate of 0.2 μl/min.
Animals were PFA-perfused 2 wk after virus injection. 40-μm thick serial coronal sections
from the SN were collected on a cryostat (Leica) and processed for immunohistochemistry.
MPTP injections and stereology in mice
MPTP injections [20] and quantification of dopaminergic neurodegeneration [47] was per-
formed as previously described. Counting of TH- and Nissl-positive neurons in the substantia
nigra was performed blind to avoid biases. For statistical analyses, a two-way ANOVA fol-
lowed by a Newman–Keuls post hoc test was performed (R software packages, version 2.8.0, R
Development Core Team 2008, Vienna, Austria).
Immunohistochemistry of mouse brain sections
Mice were transcardially perfused with 50 ml in a phosphate buffer followed by 100 ml 4%
PFA in PB at a flow rate of 15 ml/min. Brains were removed, postfixed overnight in the same
solution, then cryoprotected by immersion in 30% sucrose for 36 h. Free-floating 40 μm serial
coronal sections from throughout the SN were collected with a Cryostat (Leica Microsystems,
Germany). Brain slices were placed in a phosphate-buffered saline solution (1x PBS, 0.1%
sodium azide) and stored at 4˚C before use.
For the detection of proteins after infection, free-floating sections were washed three times
in PBS, blocked in PBS containing 4.5% bovine saline albumin (BSA) for 1 h, then incubated
for 48 h at 4˚C in PBS containing 3% BSA, 0.2% Triton X-100, and one of the following
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antibodies of interest. Sections were rinsed three times in PBS and incubated with Alexa Fluor
488-labeled antimouse or rabbit IgG or Alexa Fluor 555-labeled antimouse or rabbit IgG (Invi-
trogen) at room temperature for 1 h. The sections were rinsed in PBS and the nuclei were
counterstained with DAPI (dilution 1:10,000, Wako) for 3 min. The sections were mounted in
Mowiol.
Series of sections were immunostained for aSyn to localize the injection site in aSyn-
injected mice with anti–N-terminal aSyn antibody (Mouse, BD Transduction Laboratories,
610787). Anti-TH antibody (Rabbit, Millipore, ab152) was used to quantify the loss of dopami-
nergic (DA) neurons in the injected mice.
Quantification of neurodegeneration
The total number of DA neurons was determined by counting the number of TH-immunore-
active cells by stereology in every sixth (rat) or fourth (mouse) brain section in the region of
the SNpc (6–7 sections throughout the SN). Ventral tegmental TH-positive cells were dis-
carded. StereoInvestigator software (MicroBrightField, Bioscience) was used to count cells in
an unbiased manner. The estimation of the total number of TH-positive neurons per SNpc
was achieved using the optical fractionator method [48]. In rat brain samples, survival of DA
neurons was determined at 1, 2, and 3 wk after vector administration. In mouse brain samples,
survival was analyzed 2 wk after vector administration.
Supporting information
S1 Fig. Variation of aSyn acetylation levels with ageing. Brain protein extracts of WT
and T2.KO young (2 month) and old (8 month) mice were probed for acetyl-lysine (red) and
aSyn (green) (n = 4 per group). The ratio of acetyl-lysine/aSyn ratio is presented. p< 0.01,
 p< 0.0001, ordinary one-way ANOVA followed by Tukey’s multiple comparisons test.
Data in S1 Data.xls.
(TIF)
S2 Fig. aSyn KxK motifs are less susceptible to chemical acetylation in vitro. Peptide mass
spectrometry analysis of chemically acetylated recombinant aSyn, showing the number of acet-
ylation occurrences. Each green bar represents a detected peptide, and a red dash indicates an
acetylation.
(TIF)
S3 Fig. Acetylation-resistant aSyn mutant maintains the typical NMR signal and mem-
brane-binding ability. (A) Superposition of 2D 1H-15N HSQC NMR spectra of recombinant
15N-labelled aSyn WT (black), K6+10R (red). (D) Residue-specific changes in 1H-15N HSQC
signal intensities of aSyn WT (black) and aSyn K6+10R (red) upon addition of SUVs formed
by POPC:POPA (1:1 molar ratio). The aSyn-to-lipid molar ratio was 1:100.
(TIF)
S4 Fig. Autophagy is impaired upon T2.KD in the cell model of aSyn aggregation. Protein
extracts from Scr or T2.KD cells co-transfected with SynT and Synphilin-1 were probed for
P62 and β-Actin. Normalized levels of P62 are presented (n = 3).  p< 0.01, unpaired t-test
with equal SD. Data in S1 Data.xls.
(TIF)
S5 Fig. aSyn constructs, viral vector details, and experimental paradigm. (A) aSyn double
mutants mimicking the acetylated (KQ) or the acetylation-resistant (KR) variants of aSyn on
K6 and K10. (B) Recombinant adeno-associated viral vectors (AAV) serotype 6 expressing
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green fluorescent protein (GFP), human wild type (WT), KQ, KR variants of aSyn under the
control of human synapsin 1 promoter were produced and purified according to standard pro-
tocols. (C) Young adult female Wistar rats were stereotaxically injected on the right hemi-
sphere (brain coordinates: AP:- 4.7; ML: -2.2; DV: -7.7 mm relative to Bregma to target the
SN) with vectors encoding for GFP or aSyn variants. Abbreviations: AP, anterior-posterior;
ML, medio-lateral; DV, dentro-ventral.
(TIF)
S6 Fig. Acetylation-resistant mutant of aSyn is toxic. Lactate dehydrogenase levels (LDH)
were measured in the supernatants of primary cultures infected with AVV6 encoding for WT,
KQ or KR aSyn, at different time points after transduction. The KR mutant is toxic 3 days after
infection, and the toxicity is then indistinguishable at later time points. Data in all panels are
average ± SD,  p< 0.05, two-way ANOVA with Bonferroni correction was used for statistical
calculations (n = 4). Data in S1 Data.xls.
(TIF)
S7 Fig. Expression of WT aSyn in the SN is toxic over time. (A) Brain sections immunos-
tained for TH (red panels) and aSyn (Syn-1) (green panels) 1, 2 and 3 weeks after injection
with vectors encoding for EGFP or WT aSyn. Scale bar for isolated channels 200 μm and for
merged channels 100 μm. (B) Stereological counting of the number of TH-positive neurons in
the SN. The EGFP-injected SN of the different groups of animals was used as a control. Statisti-
cal comparisons were performed using a one-way ANOVA with Bonferroni multiple compari-
sons test (p<0.01, GFP as control; n = 5 animals per condition; six to seven sections from a 1
in 6 series were analysed per brain). Data in S1 Data.xls.
(TIF)
S8 Fig. Aggregation pattern of aSyn in the rat substantia nigra. Brain sections immunos-
tained for aggregated-aSyn (red) and GFP or pS129 aSyn (green) from representative animals
3 weeks after injection with AAV6 vectors encoding for GFP and WT, KR or KQ aSyn. (A)
5G4 and GFP (GFP group) or pS129 (aSyn groups) merged signal with DAPI is presented.
Scale bar 500 μm. (B) Higher magnification of the previous groups. Scale bar for isolated chan-
nels 50 μm and for merged channels 25 μm.
(TIF)
S1 Table. aSyn acetylation in mouse brain, identified by peptide mass fingerprint (PMF)
(trypsin digestion). Theoretical peptide mass (Da); error (ppm); Start-end identified peptides;
peptide sequences; putative acetylation residues. Oxid (M), N-terminal acetylation and acetyla-
tion (K) as variable modifications.
(DOCX)
S1 Data. Raw data. Results from Figs 1F, 2B, 2F, 3A, 3B, 4A, 4B, 4C, 5C, 6B, 7B, 7E, 7F, S1, S4,
S6 and S7B.
(XLSX)
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